Haemonetics Corporation

NYSE:HAE Stok Raporu

Piyasa değeri: US$3.7b

Haemonetics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Haemonetics şirketinin toplam hissedar öz sermayesi $905.4M ve toplam borcu $1.2B olup, bu da borç-öz sermaye oranını 135.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $2.5B ve $1.6B dir. Haemonetics 'in FAVÖK'ü $219.2M faiz karşılama oranı 11.2 dur. Şirketin $346.1M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

135.1%

Borç/özkaynak oranı

US$1.22b

Borç

Faiz karşılama oranı11.2x
NakitUS$346.07m
EşitlikUS$905.37m
Toplam yükümlülüklerUS$1.64b
Toplam varlıklarUS$2.54b

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Recent updates

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Aug 14
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Jul 18
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Jun 21

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Apr 30
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09
Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HAE 'nin kısa vadeli varlıkları ( $978.6M ) kısa vadeli yükümlülüklerini ( $260.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: HAE 'un kısa vadeli varlıkları ( $978.6M ) uzun vadeli yükümlülüklerini ( $1.4B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HAE 'nin net borç/öz sermaye oranı ( 96.9% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: HAE şirketinin borç/öz sermaye oranı son 5 yılda 75.3% seviyesinden 135.1% seviyesine yükseldi.

Borç Kapsamı: HAE 'nin borcu işletme nakit akışı ( 11.1% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: HAE 'in borcuna ilişkin faiz ödemeleri EBIT ( 11.2 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Bilanço

Sağlıklı şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y